Immunology Focus Areas:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is for UK Healthcare Professionals only

      This promotional material is intended for UK Healthcare Professionals experienced in the diagnosis and treatment of psoriasis and psoriatic arthritis. SKYRIZI® (risankizumab) and adalimumab prescribing information & adverse event reporting information can be found below.
      SKYRIZI DOSING GUIDE
      SKYRIZI PRESCRIBING INFORMATION
      ADALIMUMAB PRESCRIBING INFORMATION
      skyrizi desktop banner 7.0
      skyrizi mobile banner 2

      UK-RISN-250214. Date of preparation July 2025.

      Dosing

      Gain a clear understanding of the straightforward dosing schedule and administration process for SKYRIZI.

      4 injections per year after 2 loading doses

      *Maintenance dosing (1 injection/dose) every 12 weeks following a starter dose at Week 0 and Week 4.
      Each 150mg dose is administered as subcutaneous injections.4

      with the SKYRIZI 150mg PEN
      15 second injection time4

      A consistent dosing regimen across all SKYRIZI patients4

      If you would like downloadable versions of these videos to share with your patients please contact your AbbVie representative.

      SKYRIZI PEN Training Video

      SKYRIZI PFS Training Video

      Featured content

      How SKYRIZI (risankizumab) works differently

      Explaining how SKYRIZI works and it’s differences versus other IL-classes using a garden analogy.

      The Young Footballer Revisited

      Revisit the story of the 29-year-old footballer who achieved full clearance of his long-standing facial and scalp psoriasis with SKYRIZI, and who, more than 3 years later, continues to thrive in his personal life, no longer hiding his face.

      More expert perspectives

      View expert perspectives on SKYRIZI’s efficacy
      data, dosing regimen and safety profile.

      View now

      More expert perspectives

      View expert perspectives on SKYRIZI’s efficacy data, dosing regimen and safety profile.

      View now

      UK-RISN-260056. Date of preparation April 2026.

      Home delivery and tailored nurse services offers simple dosing and support

      • Homecare registration, delivery and injection administration providing care to your patients in their home.
      • Support that adapts to the evolving needs of your patients. With AbbVie Care patients benefit from tailored face-to-face and telephone support* from Homecare nurses. Ensuring the continuation of care from the hospital to their home.
      • Following titration one dose per delivery, minimising the risk of waste due to potential treatment changes and reducing the burden on patients by alleviating the need to store multiple doses at their own home.
      • Clinical evaluations provided by the SKYRIZI Homecare nurse so that you can feel confident knowing that your patients are supported between hospital visits.

      *Telephone support not offered in Scotland.
      AbbVie Care is developed and funded by AbbVie Ltd.
      For all patients enrolled in the homecare support program provided through AbbVie Care.

      References

      1. Reich K, et al. Lancet 2019; 394: 576-586.
      2. Gordon KB, et al. Lancet 2018; 392: 650-661. 
      3. Warren RB, et al. Br J Dermatol 2021;184:50-59
      4. SKYRIZI: Summary of Product Characteristics.

      UK-RISN-260033. Date of preparation: April 2026.

      SKYRIZI PRESCRIBING INFORMATION
      ADALIMUMAB PRESCRIBING INFORMATION

       

      Important safety information for SKYRIZI® (risankizumab) in Psoriasis and Psoriatic Arthritis¹
      SKYRIZI should be initiated and supervised by healthcare professionals experienced in the diagnosis and treatment of Psoriasis and Psoriatic arthritis.

      Some patients may not be suitable for SKYRIZI (risankizumab). You are strongly advised to read the prescribing information, which can be found at the top of this webpage and below, and the Summary of Product Characteristics (SmPC) which are available online in the Electronic Medicines Compendium (EMC) from the links below.

      SKYRIZI 150 mg solution for injection in pre-filled pen CLICK HERE.
      SKYRIZI 150 mg solution for injection in pre-filled syringe CLICK HERE.

      SKYRIZI PRESCRIBING INFORMATION CLICK HERE.

      SKYRIZI is contraindicated in patients;

      • with hypersensitivity to the active substance or to any of the excipients,
      • with clinically important active infections (e.g. active tuberculosis).

      Cautions (See Prescribing Information and SmPC for full details including screening and monitoring requirements):
      It is preferable to avoid the use of SKYRIZI during pregnancy. Women of childbearing potential should use an effective method of contraception during treatment and for at least 21 weeks after treatment. It is unknown whether risankizumab is excreted in human milk. A decision should be made whether to discontinue/abstain from risankizumab therapy, taking into account the benefit of breast-feeding to the child and the benefit of risankizumab therapy to the woman.

      Dosing in Psoriasis and Psoriatic Arthritis
      The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.

      Adverse reactions
      For adverse reactions, please refer to the prescribing information and the SKYRIZI summary of product characteristics available online in the Electronic Medicines Compendium via the links above.

      Important safety information for HUMIRA® (adalimumab) in Psoriasis and Psoriatic Arthritis²
      HUMIRA is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which HUMIRA is indicated.

      Psoriatic arthritis: HUMIRA is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. HUMIRA has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function.
      Psoriasis: HUMIRA is indicated for the treatment of moderate-to-severe chronic plaque psoriasis in adult patients who are candidates for systematic therapy

      Paediatric plaque psoriasis: HUMIRA is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.

      Some patients may not be suitable for HUMIRA. You are strongly advised to read the prescribing information, which can be found at the top of this webpage and below, and the Summary of Product Characteristics (SmPC) which are available online in the Electronic Medicines Compendium (EMC).

      HUMIRA 40 mg solution for injection in pre-filled pen CLICK HERE.

      ADALIMUMAB PRESCRIBING INFORMATION CLICK HERE.

      References
      1. SKYRIZI Summary of Product Characteristics
      2. HUMIRA Summary of Product Characteristics

      Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the Google Play or Apple App Stores. Adverse events should also be reported to AbbVie on GBPV@abbvie.com

       

      This website is for UK Healthcare Professionals only

      UK-ABBV-250400. Date of preparation December 2025. This website has been developed and funded by AbbVie Ltd.

      © 2023 AbbVie Ltd. All rights reserved. Registered Number: 08004972 England.